Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bioventix PLC specializes in the development and commercialization of monoclonal antibodies for use in the in vitro diagnostics market, particularly focusing on cardiac and hormone testing. The company's competitive position is strengthened by its proprietary technology and high gross margins, which are significantly above industry averages.
Bioventix generates revenue primarily through the sale of its proprietary monoclonal antibodies to diagnostic manufacturers. The high gross margin of 90.9% reflects strong pricing power due to the specialized nature of its products and limited competition in its niche market.
New product approvals in cardiac and hormone diagnostics
Changes in healthcare regulations affecting diagnostic testing
Partnerships or collaborations with major diagnostic manufacturers
Market demand for in vitro diagnostic tests
Regulatory changes in the healthcare sector that could impact product approvals
Technological advancements by competitors that may render current products obsolete
Emergence of new competitors in the monoclonal antibody space
Potential for pricing pressure from larger diagnostic firms
Limited cash flow generation could restrict investment in R&D
Dependence on a small number of key products for revenue
low - The demand for in vitro diagnostics is relatively inelastic and less sensitive to economic cycles compared to other sectors.
Minimal impact as Bioventix operates with no debt and is not reliant on external financing, though higher rates could indirectly affect healthcare spending.
minimal
growth - Investors are likely attracted to Bioventix for its high gross margins and potential for market expansion in the diagnostics sector.
moderate - The stock has shown volatility with a 1-year return of -41.1%, indicating sensitivity to market conditions and company performance.
